Research Institute of Molecular Pathology (IMP)
Thomas Williams is a skilled postdoctoral researcher currently at the Research Institute of Molecular Pathology, focusing on protein engineering and synthetic biology to explore the ubiquitin machinery and post-translational modifications. Prior experience includes research on oxidised phospholipids in blood coagulation and aortic aneurysms at Cardiff University, along with roles in analytical chemistry, where expertise in high-resolution LC and GC-MS techniques was applied. Thomas also has a background in customer service and teaching, having lectured at the University of South Wales and worked as a sales assistant at Next Group PLC. Academic qualifications include a PhD in Chemistry and a Master's in Forensic Science and Technology from Cardiff University and the University of South Wales, respectively.
Research Institute of Molecular Pathology (IMP)
The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by Boehringer Ingelheim. With over 200 scientists from 40 countries, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. Research areas include cell and molecular biology, microscopy, immunology and cancer, developmental biology, chromosome biology, and computational biology.